AstraZeneca's LYNPARZA® (olaparib) receives FDA Approval for new indication
J-code Now Available for MYLOTARG™ (gemtuzumab ozogamicin)
C-code Now Available for BESPONSA™ (inotuzumab ozogamicin)
Fresenius Kabi USA, LLC, receives FDA approval for its BORTEZOMIB for injection
Eli Lilly's LARTRUVOTM (olaratumab) injection receives HCPCS J-Code: J9285
Follow RMOS on Twitter
What's New @ RMOS:
Starting January 1, FDA grants BAVENCIO® (avelumab) injection the following permanent HCPCS J-Code:J9023
RMOS Sponsors Colorado Cancer Coalition Symposium. Register Today!
Did You Miss Our Symposium on Immune-Related Adverse Events (irAEs)? Get Access to the Recording!
RMOS Submits Letter Regarding Medicare Part B to Department of Health and Human Services
AstraZeneca's TAGRISSO® (osimertinib) Receives FDA Full Approval
| ACCC Resources
| ASCO Resources
| ASCO Connection |
© Oncology State Society Network. All rights reserved.